- Home
- MRAM vs CRDF Comparison
MRAM vs CRDF Comparison
Compare MRAM & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- CRDF
- Stock Information
- Founded
- MRAM 2008
- CRDF 1999
- Country
- MRAM United States
- CRDF United States
- Employees
- MRAM N/A
- CRDF N/A
- Industry
- MRAM Semiconductors
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRAM Technology
- CRDF Health Care
- Exchange
- MRAM Nasdaq
- CRDF Nasdaq
- Market Cap
- MRAM 131.1M
- CRDF 143.4M
- IPO Year
- MRAM 2016
- CRDF N/A
- Fundamental
- Price
- MRAM $5.87
- CRDF $2.58
- Analyst Decision
- MRAM Strong Buy
- CRDF Strong Buy
- Analyst Count
- MRAM 2
- CRDF 3
- Target Price
- MRAM $9.00
- CRDF $9.33
- AVG Volume (30 Days)
- MRAM 122.9K
- CRDF 1.1M
- Earning Date
- MRAM 10-30-2024
- CRDF 11-07-2024
- Dividend Yield
- MRAM N/A
- CRDF N/A
- EPS Growth
- MRAM N/A
- CRDF N/A
- EPS
- MRAM 0.07
- CRDF N/A
- Revenue
- MRAM $53,865,000.00
- CRDF $688,000.00
- Revenue This Year
- MRAM N/A
- CRDF $15.00
- Revenue Next Year
- MRAM $7.15
- CRDF N/A
- P/E Ratio
- MRAM $82.31
- CRDF N/A
- Revenue Growth
- MRAM N/A
- CRDF 49.57
- 52 Week Low
- MRAM $4.89
- CRDF $1.07
- 52 Week High
- MRAM $9.44
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- MRAM 44.39
- CRDF 41.24
- Support Level
- MRAM $5.78
- CRDF $2.85
- Resistance Level
- MRAM $6.23
- CRDF $4.38
- Average True Range (ATR)
- MRAM 0.27
- CRDF 0.45
- MACD
- MRAM -0.05
- CRDF -0.10
- Stochastic Oscillator
- MRAM 9.60
- CRDF 2.70
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").